<DOC>
	<DOCNO>NCT00263029</DOCNO>
	<brief_summary>The purpose phase II trial determine efficacy safety combination oxaliplatin , capecitabine radiotherapy preoperative therapy locally advance cancer rectum .</brief_summary>
	<brief_title>Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>ECOG performance status score 01 . Chemona√Øve patient . Histologically/cytologically confirm diagnosis rectal adenocarcinoma ( clinically stage mT3 mT4 ) , either consider ( 1 ) inoperable , ( 2 ) locally advanced , histologically confirm curative resection consider unlikely . Evaluable measurable disease image MRI/CT allow response assessment . Adequate haematological , renal liver function follow : ANC &gt; 3000ml Platelet count &gt; 100,000 ml Urea &amp; Serum Creatinine &lt; 1.5 X upper limit normal value Total serum bilirubin &lt; 1.5 X upper limit normal value ALT &amp; AST &lt; 3 X upper limit normal value Prior chemotherapy . Documented allergy oxaliplatin capecitabine . Prior radiotherapy pelvis . Previous concurrent malignancy sit exception basal squamous cell carcinoma skin . Pregnant lactating female ( negative pregnancy test documentation premenopausal female patient ) . Currently participate another clinical trial investigational drug previous 30 day . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>